Biotech IPO performance pokes holes in Silicon Valley's theory for waiting so long to go public
May 20, 2019 at 14:26 PM EDT
Silicon Valley argues that the public market investors focus too much on near-term profits — but investors have embraced money-losing biotech IPOs.
